Abstract: Provided is an ophthalmic composition comprising a rifamycin compound. A topical eye drop composition, which comprises an aqueous solution formulation comprising an effective amount of a rifamycin compound selected from the group consisting of rifampicin, rifabutin, rifapentine, and rifaximin, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier, a buffer solution, and 0.00001% to 50% by weight of a nonionic surfactant.

Abstract: Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations.

Abstract: Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underlying acne symptoms such as skin redness.

Abstract: Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations.

Abstract: Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underlying acne symptoms such as skin redness.

Abstract: Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underlying acne symptoms such as skin redness.

Abstract: Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations.

Abstract: Topical administration of VEGF inhibitors such as, without limitation, rifamycin compounds are useful for treating skin disorders such as treating and/or reducing scars such as hypertrophic scars, and useful for treating acne and underlying acne symptoms such as skin redness.

Abstract: Provided herein are ophthalmic pharmaceutical formulations comprising a rifamycin compound. Also provided herein are methods of treating ocular diseases or disorders by administering such ophthalmic formulations. This invention relates generally to pharmaceutical compositions or formulations suitable for administration to an eye. In some aspects, this invention relates to ophthalmic pharmaceutical compositions or formulations comprising one or more rifamycin compounds selected from the group consisting of rifampicin, rifabutin, rifapentine. In one aspect, the invention relates to methods of treating an ocular disease, disorder or condition comprising administering to a patient in need thereof an ophthalmic composition comprising an effective amount of a rifamycin compound selected from the group consisting of rifampicin, rifabutin, rifapentine, and rifaximin.

Abstract: Provided herein are methods for improving negative effects of ALS, AD, or ischemia, the methods comprising administering to a subject in need thereof a therapeutically effective amount of GGA, preferably present in the trans form, or a derivative thereof.

Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

Abstract: Provided herein is a pharmaceutical formulation comprising a GGA derivative in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Abstract: Provide herein are methods of treating inflammatory bowel disease with geranylgeranyl acetone (GGA) and/or derivatives thereof. Also provided are methods of treating chronic liver disease (CLD) with geranylgeranyl acetone (GGA) and/or derivatives thereof. Still further are provided methods for treating other hepatic and cardiac disorders.

Abstract: Provide herein are intranasal compositions which include geranylgeranyl acetone (GGA) and/or derivatives thereof and methods for treating a neural disease, disorder or condition with the same.

Abstract: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Abstract: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Abstract: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.

Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

Abstract: Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of a transdermal patch. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations.